GettyImages-609179959-hero

Cardiac Amyloid Program

Clinical Staff 2F 2M

About Cardiac Amyloidosis

Amyloidosis is a condition in which a pathologic substance called amyloid deposits in various tissues in the body. Amyloid is composed of proteins which undergo changes allowing them to form into insoluble fibrils. These fibrils can deposit in different tissues or organs (e.g., heart, liver, kidney, skin, eyes, lungs, nervous system) resulting in a variety of clinical manifestations and potentially life-threatening organ failure. Cardiac involvement is a progressive disorder which may result in early death due to congestive heart failure (CHF) and arrhythmias. Cardiac involvement can also occur as part of a systemic disease or as a localized phenomenon.

Meet Our Team

headshot

Christopher Mueller, MD, FACC

Assistant Professor of Medicine

headshot

Anita D'Souza, MD

Associate Professor

headshot

Parameswaran Hari, MD, MRCP

Chief, Professor

headshot

Bhavna Bhasin, MD

Assistant Professor

headshot

Naveen Kumar Addagatla, MBBS

Assistant Professor

headshot

Juan Jose Figueroa, MD

Assistant Professor

Collaboration Table 2F 3M

About the Cardiac Amyloidosis Clinic

At the Medical College of Wisconsin our physicians have a level of experience and training in Amyloidosis not commonly found in Wisconsin. We provide exemplary care to our patients with all types of amyloidosis. We have expertise in nuclear scintigraphy (TC 99 pyp), cardiac ultrasound (including 3D and strain imaging) and cardiac MRI which allows us to utilize the most advanced technology when it comes to diagnosis and management of this disease process. As amyloidosis can affect several different body systems, we have developed a team of Hematologists, Nephrologists, Cardiologists, Pulmonologists, Neurologists, and Pathologists to offer the best and most comprehensive care available.

We are committed to developing a plan that is right for your patients. We also have access to several clinical trials which may offer additional options for therapy and new insights into current therapy as well as markers of prognosis and disease severity.

Comprehensive Treatment Options

There are several types of amyloidosis; the two most commonly affecting the heart are:

  • AL Amyloidosis: amyloid fibrils are composed of immunoglobulin light chain proteins produced in the bone marrow and most commonly affect the heart, kidneys, skin, nerves, and liver.
  • ATTR Amyloidosis: can be based on a genetic mutation in the transthyretin protein (variant or ATTRv) or acquired (wild type or ATTRwt).
    • Hereditary (variant, ATTRv) transthyretin amyloidosis is an autosomal dominant, multi-organ, progressive, life-threatening disease caused by mutations in the gene encoding TTR production by the liver. The most common ATTRv mutation in the US is V122I. It affects 3-4% of African American population with variable penetrance.
    • Wild-type ATTR (ATTRwt) amyloidosis is a slowly progressive disease, typically affecting patients over age 65. The disease typically is manifested as heart failure with preserved ejection fraction, atrial fibrillation, and neuropathy.

There is currently no cure for amyloidosis, but treatments are available which manage symptoms and limit the production of the amyloid protein with the goal to ultimately slow or stop the disease process and improve morbidity and mortality.

Learn more about treatment options

Contact Us

To transfer a patient or consult with a specialist (for physicians and staff only):
Call the Access Center at (414) 805-4700 or (877) 804-4700.

 

Nurses are available 24 hours a day, seven days a week.

 

Patient Information
Please call 1-800-DOCTORS to make an appointment in the Cardiovascular Medicine clinic.

Medical College of Wisconsin Google map location